MBX Stock Analysis: Buy, Sell, or Hold?
MBX - MBX Biosciences, Inc. Common Stock
$66.33
-0.02 (-0.03%)
âŧ
5d:
-3.27%
30d:
+4.34%
90d:
+108.65%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When MBX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MBX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MBX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MBX is currently trading at $66.33, which is considered fair relative to its 30-day fair value range of $61.38 to $68.06.
Technical Outlook: Technically, MBX is in a strong uptrend. The price is currently testing key support at $65.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MBX scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $88.40 (+33.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MBX is in a strong uptrend. The price is currently testing key support at $65.01. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MBX scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $88.40 (+33.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$61.38 -
$68.06
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 33.3% below Wall St target ($88.40)
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$61.38 -
$68.06
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$65.01
Resistance Level
$69.94
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.83
Wall Street Target
$88.40
(+33.3%)
Share & Embed Analysis
Last updated: August 23, 2026 9:48 AM ET
Data refreshes hourly during market hours. Next update: 10:48 AM
Data refreshes hourly during market hours. Next update: 10:48 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MBX showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
P. Kent Hawryluk
BUY
18500 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 55 HOLD |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$39 | 52 HOLD |
